Roots Analysis Identifies 7 Companies in Subcutaneous Biologics Formulation Technology
Roots Analysis has identified seven companies advancing the development of subcutaneous biologics through their formulation technologies. These technologies aim to improve drug delivery and patient compliance.
Research firm Roots Analysis has released a report identifying seven key companies focused on developing formulation technologies for subcutaneous biologics.
The report highlights companies providing technological platforms that enable more effective delivery of biologic drugs beneath the skin. This approach is designed to enhance patient convenience and adherence to treatment, particularly for individuals managing chronic conditions like diabetes and rheumatoid arthritis.
Historically, many biologics required administration via injection or intravenously, often necessitating clinic or hospital visits. The advancement of subcutaneous formulations allows for self-administration using devices such as prefilled syringes or auto-injectors, potentially reducing patient burden and healthcare costs.
Roots Analysis surveyed over 150 companies involved in developing subcutaneous biologics or related formulation technologies. The seven companies featured in the report were selected based on their technological capabilities and market presence, with a focus on firms established between 2005-2008 and employing 51-1,000 individuals.
The identified companies include Adocia, Alteogen, Ascendis Pharma, Creative Biolabs, Creative Biomart, Pacira BioSciences, and Xeris Biopharma, representing leaders in efforts to improve biologic drug delivery methods and efficacy.